Related Experiment Video
Updated: Jul 18, 2026

Suppression of Pro-fibrotic Signaling Potentiates Factor-mediated Reprogramming of Mouse Embryonic Fibroblasts into Induced Cardiomyocytes
Published on: June 3, 2018
Bone marrow-derived fibroblast precursors mediate ischemic cardiomyopathy in mice
Sandra B Haudek1, Ying Xia, Peter Huebener
1DeBakey Heart Center, Baylor College of Medicine, Methodist Hospital, Houston, TX 77030, USA.
Abstract:
We previously described a mouse model of fibrotic ischemia/reperfusion cardiomyopathy (I/RC) arising from daily, brief coronary occlusion. One characteristic of I/RC was the prolonged elevation of monocyte chemoattractant protein 1 (MCP-1), which was obligate to its phenotype and may contribute to the uptake of bloodborne cells. Here we describe in I/RC hearts a population of small spindle-shaped fibroblasts that were highly proliferative and expressed collagen I and alpha-smooth muscle actin (myofibroblast markers), CD34 (a precursor marker), and CD45 (a hematopoietic marker). These cells represented 3% of all nonmyocyte live cells. To confirm the cells' bone marrow origin, chimeric mice were created by the rescue of irradiated C57BL/6 mice with marrow from ROSA26, a congenic line expressing lacZ. I/RC resulted in a large population of spindle-shaped fibroblasts containing lacZ. We postulated that the fibroblast precursors represented a developmental path for a subset of monocytes, whose phenotype we have shown to be influenced by serum amyloid P (SAP). Thus, we administered SAP in vivo, which markedly reduced the number of proliferative spindle-shaped fibroblasts and completely prevented I/RC-induced fibrosis and global ventricular dysfunction. By contrast, SAP did not suppress the inflammation or chemokine expression seen in I/RC. SAP, a member of the pentraxin family, binds to Fcgamma receptors and modifies the pathophysiological function of monocytes. Our data suggest that SAP interferes with assumption of a fibroblast phenotype in a subset of monocytes and that SAP may be an important regulator in the linkage between inflammation and nonadaptive fibrosis in the heart.
Insights
Serum amyloid P (SAP) prevents monocyte-derived fibroblasts and cardiac fibrosis in a mouse model of ischemia/reperfusion cardiomyopathy (I/RC). SAP administration blocked fibrosis without affecting inflammation, suggesting a role in regulating inflammation-fibrosis linkage.
Area of Science:
- Cardiovascular Research
- Fibrosis Mechanisms
- Immunology
Background:
- Ischemia/reperfusion cardiomyopathy (I/RC) involves prolonged monocyte chemoattractant protein 1 (MCP-1) elevation.
- I/RC hearts exhibit proliferative spindle-shaped fibroblasts expressing myofibroblast, precursor, and hematopoietic markers.
Purpose of the Study:
- To investigate the origin and therapeutic targeting of fibroblasts in I/RC.
- To explore the role of serum amyloid P (SAP) in modulating I/RC-induced cardiac remodeling.
Main Methods:
- Created chimeric mice by bone marrow transplantation to trace fibroblast origin.
- Administered SAP in vivo to I/RC mouse models.
- Assessed cardiac fibrosis, ventricular dysfunction, inflammation, and chemokine expression.
Main Results:
- Fibroblasts in I/RC hearts were confirmed to be of bone marrow origin.
- SAP administration significantly reduced proliferative fibroblasts and completely prevented I/RC-induced fibrosis and ventricular dysfunction.
- SAP did not suppress inflammation or chemokine expression in I/RC hearts.
Conclusions:
- SAP interferes with monocyte differentiation into fibroblasts, offering a potential therapeutic strategy for I/RC.
- SAP may be a key regulator linking cardiac inflammation and nonadaptive fibrosis.

